Bioventus Inc. focuses on developing and commercializing treatments that engage and enhance the body's natural healing process. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries. Restorative therapies comprise an ultrasonic bone healing system for fracture care.
Market Cap | 316.476 Million | Shares Outstanding | 62.793 Million | Avg 30-day Volume | 238.342 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.76 |
Price to Revenue | 0.4124 | Debt to Equity | 1.7426 | EBITDA | -95.213 Million |
Price to Book Value | 1.1678 | Operating Margin | -36.268299999999996 | Enterprise Value | 617.173 Million |
Current Ratio | 1.551 | EPS Growth | -0.432 | Quick Ratio | 0.869 |
1 Yr BETA | 1.4679 | 52-week High/Low | 5.52 / 0.8 | Profit Margin | -46.3131 |
Operating Cash Flow Growth | 280.3319 | Free Cash Flow to Firm (FCFF) TTM | 41.114 Million | Free Cash Flow to Equity (FCFE) TTM | 20.084 Million |
Altman Z-Score | -0.2661 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BIHL ANTHONY P III INTERIM CEO |
|
164,885 | 2023-08-18 | 4 |
|
69,717 | 2023-08-16 | 3 | |
|
13,660,305 | 2023-08-11 | 8 | |
|
13,610,268 | 2023-08-10 | 2 | |
CHURCH KATRINA J SVP & CHIEF COMPLIANCE OFFICER |
|
11,828 | 2023-07-03 | 3 |
D'ADAMIO ANTHONY SVP & GENERAL COUNSEL |
|
45,610 | 2023-06-20 | 1 |
SINGLETON MARK LEONARD SVP & CFO |
|
12,581 | 2023-06-20 | 4 |
|
18,578 | 2023-06-16 | 2 | |
|
20,274 | 2023-06-16 | 2 | |
|
17,419 | 2023-06-16 | 2 | |
JUNIPER INVESTMENT COMPANY, LLC JUNIPER TARGETED OPPORTUNITIES, LP |
|
6,327,264 | 2023-06-12 | 2 |
|
13,049,672 | 2023-06-06 | 1 | |
|
200,958 | 2023-06-06 | 2 | |
|
49,064 | 2023-06-06 | 1 | |
|
28,348 | 2023-06-06 | 1 | |
|
2,800,466 | 2022-06-16 | 0 | |
|
11,700 | 2022-04-01 | 0 | |
PAVESIO ALESSANDRA SVP & CHIEF SCIENCE OFFICER |
|
329,615 | 2022-04-01 | 0 |
NOSENZO JOHN FMR. CHIEF COMMERCIAL OFFICER |
|
87,148 | 2022-04-01 | 0 |
REALI KENNETH MICHAEL CHIEF EXECUTIVE OFFICER |
|
30,085 | 2022-03-14 | 0 |
ANGLUM GREGORY O. SVP & CFO |
|
111,320 | 2022-02-11 | 0 |
|
2,700 | 2021-04-01 | 0 | |
|
21,963,494 | 2021-02-11 | 0 | |
EW HEALTHCARE PARTNERS ACQUISITION FUND, L.P. EW HEALTHCARE PARTNERS ACQUISITION FUND GP, L.P. |
|
13,021,324 | 2021-02-11 | 0 |
|
3,906,395 | 2021-02-11 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
BIOVENTUS INC - A BVS | 2023-12-08 22:15:04 UTC | -1.2082 | 6.5282 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 21:45:04 UTC | -1.2082 | 6.5282 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 21:15:04 UTC | -1.2082 | 6.5282 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 20:45:04 UTC | -1.2082 | 6.5282 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 20:15:07 UTC | -1.1261 | 6.4461 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 19:45:04 UTC | -1.1261 | 6.4461 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 19:15:03 UTC | -1.111 | 6.431 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 18:45:03 UTC | -1.111 | 6.431 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 18:15:04 UTC | -1.111 | 6.431 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 17:45:03 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 17:15:03 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 16:45:05 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 16:15:04 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 15:45:04 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 15:15:04 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 14:45:04 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 14:15:03 UTC | -1.0742 | 6.3942 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 13:45:03 UTC | 0.4935 | 4.8265 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 13:15:04 UTC | 0.4935 | 4.8265 | 1200000 |
BIOVENTUS INC - A BVS | 2023-12-08 12:45:05 UTC | 0.4935 | 4.8265 | 1200000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|